Glaucoma and ocular hypertension. Reduction of Elevated Intraocular Pressure in Paediatric Patients with Elevated Intraocular Pressure and Paediatric Glaucoma.
Latanoprost is a prostaglandin F2a analogue. It is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor.
One eye drop in the affected eye(s) once a day in the evening.
Pigmentation: pigmentation of the iris, periorbital tissue (eyelid)and eyelashes can occur. Iris pigmentation likely to be permanent.Eyelash Changes: gradual change to eyelashes including increasedlength, thickness and number of lashes. Usually reversible.Caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.Contact lenses should be removed prior to the administration.
There are no adequate and well-controlled studies in pregnant women, nursing woman. Safety and effectiveness in infants below the age of one year have not been established.
In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with this product.If such drugs areused, they should be administered at least 5 minutes apart
Eyelash changes (increased length, thickness, pigmentation, and number of lashes); eyelid skin darkening; intraocular inflammation (iritis/uveitis); iris pigmentation changes; macular edema,blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, punctate epithelial keratopathy, and upper respiratory tract infection/cold/flu
Protect from light. Store unopened bottle(s) under refrigeration at 2° to 8°C.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS